SGT003 / Hotgen Biotech, Beijing Sungen Biomedical Technology - LARVOL DELTA

Preclinical Characterization of SGT003, a Novel Bispecific Antibody Targeting CCR8 and CTLA-4, for Advanced Solid Tumor Immunotherapy (ESMO 2026) - No abstract available

Bispecific • Metastases • Preclinical • Oncology • Solid Tumor • CCR8

A Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, Immunogenicity, and Preliminary Efficacy of SGT003 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=332 | Recruiting | Sponsor: Beijing Sungen Biomedical Technology Co., Ltd

First-in-human • New P1/2 trial • Oncology • Solid Tumor